Valion Bio Inc VBIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surge
-
Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand to Support Data Centers
-
New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the Advancement of Entolimod
-
Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term Opportunity
-
Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions
-
Valion Bio Regains Compliance with NASDAQ Minimum Bid Price Listing Rule
-
Valion Bio Announces Changes to Management and Board of Directors
-
Valion Bio Announces Reverse Stock Split
Trading Information
- Previous Close Price
- $1.55
- Day Range
- $1.44–1.53
- 52-Week Range
- $1.44–75.75
- Bid/Ask
- $1.41 / $1.92
- Shares Outstanding
- 1.95M
- Market Cap
- $1.29M
- Volume/Avg
- 5,496 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.97
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 52
- Website
- —
Valuation
|
Metric
|
VBIO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.06 |
Price/Sales | 0.97 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VBIO
|
|---|---|
Quick Ratio | 0.69 |
Current Ratio | 1.11 |
Interest Coverage | −11.44 |
Quick Ratio
VBIO
Profitability
|
Metric
|
VBIO
|
|---|---|
Return on Assets (Normalized) | −75.62% |
Return on Equity (Normalized) | −206.56% |
Return on Invested Capital (Normalized) | −95.18% |
Return on Assets
VBIO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|G>Z<D@# | LOCK|Sz$> | $126B | |||
| Moderna Inc
MRNA
| LOCK|wf&ynYQ | LOCK|Pc | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|fLZl^#X | LOCK|^?@V< | $80B | |||
| argenx SE ADR
ARGX
| LOCK|K&LnXML | LOCK|!> | $53B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|ML?M&$f | LOCK|!? | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|C&PvNZ! | LOCK|$vkP@ | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Z@w>r^Tz | LOCK|^fyf | $26B | |||
| Incyte Corp
INCY
| LOCK|T&&$%c> | LOCK|$^ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|sqY#%vd | LOCK|z& | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|#ffR^ws | LOCK|lGD | $14B |
United States